Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 24Lymphoma 22Breast Neoplasms 20Prostatic Neoplasms 15Colorectal Neoplasms 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lung Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 12Myelodysplastic Syndromes 12Lymphoma, Large B-Cell, Diffuse 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Triple Negative Breast Neoplasms 8Rectal Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Sarcoma 7Lymphoma, Follicular 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Non-Hodgkin 6Glioma 6Fallopian Tube Neoplasms 6Cholangiocarcinoma 6

Interventions

Vincristine 2Methotrexate 2Mercaptopurine 2Hydrocortisone 2Cytarabine 2prednylidene 1pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Prednisolone 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Epirubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Down Syndrome × Biopsy × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡